24. Steelman LS, Chappell WH, Abrams SL, Kempf CR, Long J, Laidler P, Mijatovic S, Maksimovic-Ivanic D, Stivala F, Mazzarino MC, Donia M.
Roles of the Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR pathways in controlling growth and sensitivity to therapy-implications for cancer and aging. Aging 2011; 3(3): 192-222.
26. Bononi A, Agnoletto C, De Marchi E, Marchi S, Patergnani S, Bonora M, Giorgi C, Missiroli S, Poletti F, Rimessi A, Pinton P.
Protein kinases and phosphatases in the control of cell fate. Enzyme Res 2011; 2011: 329098.
51. Williams C, Brunskill S, Altman D, Briggs A, Campbell H, Clarke M, Glanville J, Gray A, Harris A, Johnston K, Lodge M.
Cost-effectiveness of using prognostic information to select women with breast cancer for adjuvant systemic therapy. Health Technol Assess 2006; 10(34): 1-204.
56. Børresen AL, Andersen TI, Garber J, Barbier-Piraux N, Thorlacius S, Eyfjörd J, Ottestad L, Smith-Sørensen B, Hovig E, Malkin D, Friend SH.
Screening for germ line TP53 mutations in breast cancer patients. Cancer Res 1992; 52(11): 3234-3236.
57. Bell DW, Varley JM, Szydlo TE, Kang DH, Wahrer DC, Shannon KE, Lubratovich M, Verselis SJ, Isselbacher KJ, Fraumeni JF, Birch JM.
Heterozygous germ line hCHK2 mutations in Li-Fraumeni syndrome. Science 1999; 286(5449): 2528-2531.
58. Staalesen V, Knappskog S, Chrisanthar R, Nordgard SH, Løkkevik E, Anker G, Østenstad B, Lundgren S, Risberg T, Mjaaland I, Gram IT.
The novel p21 polymorphism p21G251A is associated with locally advanced breast cancer. Clin Cancer Res 2006; 12(20): 6000-6004.